First North American Clinical Trial with Popular St. JohnÃs Wort
When: Monday, June 1, 1998 at 10:30 a.m.
Where: Founders Club, Skydome
1 Blue Jays Way, Toronto, Ontario
The first ever head to head study in North America comparing St. JohnÃs Wort with standard prescription drug treatment for depression has just been launched, following several European clinical studies. Dr. Jonathan Davidson, Director of the Anxiety and Traumatic Stress Center at Duke University and Principal Investigator of the National Institute of Mental Health (NIMH) study on St. JohnÃs Wort will be attending this yearÃs American Psychiatric Association (APA) Annual Meeting in Toronto. Dr. Davidson will lead a panel of medical experts who will discuss the clinical use of St. JohnÃs Wort to treat depression. Leading Canadian psychiatrist, Dr. Jacques Bradwejn, who helped design and plan the study, will provide a Canadian psychiatric perspective on using St. JohnÃs Wort to treat depression.
The panel will be moderated by Dr. Joel Raskin, psychiatrist and head of the Depression Clinic at the newly formed Centre for Addictions and Mental Health (formerly the Clarke Institute). Dr. Richard Middleton, Technical Manager at Lichtwer Pharma UK, a leading pharmaceutical company dedicated to research in plant medicines will speak about the European St. JohnÃs Wort experience. Dr. Michael Evans, a leading pioneer in the use of natural remedies, will provide his perspective as a general practitioner and the role of St. JohnÃs Wort to treat depression.
For more information, please contact: Natalie Pavlenko/Amanda Furlong (416) 413-4649/ (416) 413-4738 1-800-565-4535 Hill and Knowlton Canada Limited
B roll is being transmitted on Monday, June 1 from 2:00 - 2:30 p.m. Telestar 5 Transponder 15 Downlink 4000 AUDIO: 6.2 6.8
RSS